Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC

Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.

Related Keywords

Spain ,Massachusetts ,United States ,Virginia ,Boston ,Charlottesville ,Italy ,Milan ,Lombardia ,University Of Virginia ,Barcelona ,Comunidad Autonoma De Cataluna ,Maria Rosario Garcia Campelo ,Ryand Gentzler ,Enriqueta Felip ,Merck Serono ,Antonio Passaro ,Daiichi Sankyo ,Zofia Piotrowska ,Eli Lilly ,Society For Immunotherapy Of Cancer ,Jazz Pharmaceuticals ,University Hospitala Coru ,European Institute Of Oncology ,Glaxosmithkline ,Janssen Pharmaceuticals ,Novartis ,Bristol Myers Squibb ,Investigational Drug Steering Committee ,Boehringer Ingelheim ,Hebron University Hospital ,Pfizer ,European Lung Cancer Congress ,Hoosier Cancer Research Network ,Cancer Center ,Drug Administration ,Genentech ,Amgen ,Big Ten Research Consortium ,Scientific Review Committee ,Alliance Foundation ,Division Of Thoracic Oncology ,Astrazeneca ,Thoracic Clinical Trial Working Group ,Thoracic Oncology ,European Institute ,Medscape Medical ,University Hospital ,Massachusetts General Cancer Center ,Medical Trends ,Medscape Medical News ,Merck Sharp ,Turning Point Therapeutics ,Jounce Therapeutics ,Clinical Care Options ,Targeted Oncology ,International Association ,Lung Cancer ,Blueprint Medicines ,Review Committee ,Clinical Oncology ,Drug Steering ,